Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression
Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0976
Full Text
Open PDFAbstract
Available in full text
Date
May 15, 2019
Authors
Publisher
American Association for Cancer Research (AACR)